What is Cotinga Pharmaceuticals Inc. (COTQF)?

Cotinga Pharmaceuticals Inc. (COTQF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of COTQF?

The current price of COTQF is $0.00. Prices are updated in real time on Stocks360.

What is COTQF's price-to-earnings (PE) ratio?

COTQF's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is COTQF's market capitalization?

COTQF's market capitalization is $2,199.00, placing it in the small-cap tier.

Cotinga Pharmaceuticals Inc. (COTQF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$2.20K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-9.29

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

0.00

Cotinga Pharmaceuticals Inc. (COTQF) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $2.20K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Apr 3, 2018

EPS $-0.06 vs est. $-0.11

Beat by $0.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	-0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	0.01×
EV / Sales	0.00×
Earnings Yield	-91318.30%
Free Cash Flow Yield	-57631.25%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$16.12K
Net Income (TTM)	-$2.01M
Free Cash Flow (TTM)	-$1.27M
Net Debt	-$18.32K
Working Capital	-$2.34M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	132.92%
Return on Invested Capital	122.61%